Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543087 · ClinicalTrials.gov registry record · Phase 3
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 698
- Enrollment target
NCT01543087 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 698 participants.
The verdict
NCT01543087, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 698 participants
- Enrollment target
Study Summary
This study is to assess the longevity of immune response in adolescents for approximately 48 months after receipt of a primary series of bivalent rLP2086 vaccination, which is then followed by a booster dose and an assessment of immune response for 12 or 26 months post booster vaccination.
Interventions
- PROCEDURE blood sampling
- DRUG bivalent rLP2086
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 698 participants |
| Start Date | 2012-09-07 |
| Est. Completion | 2018-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01543087
The ClinicalTrials.gov registry entry for NCT01543087 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 698 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which blood sampling is the first listed.
NCT01543087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01543087 about?
NCT01543087 is a clinical study titled "Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose". This study is to assess the longevity of immune response in adolescents for approximately 48 months after receipt of a primary series of bivalent rLP2086 vaccination, which is then followed by a booster dose and an assessment of immune response for 12 or 26 months post booster vaccination.
What is the current status of trial NCT01543087?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 698 participants. The study started on 2012-09-07. Estimated completion is 2018-01-05.
What interventions are being tested in trial NCT01543087?
The interventions under investigation include: blood sampling (PROCEDURE), bivalent rLP2086 (DRUG).
Who is sponsoring clinical trial NCT01543087?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.